Search

Background: Persistent respiratory symptoms and lung abnormalities post‐COVID‐19 are public health problems. This study evaluated biomarkers to stratify high‐risk patients to the development or persistence of post‐COVID‐19 interstitial lung disease. Methods: One hundred eighteen patients discharged with residual lung abnormalities compatible with interstitial lung disease (COVID‐ILD patients) after a severe COVID‐19 were followed for 1 year (post‐COVID‐ILD patients). Physical examination, pulmonary function tests, and chest high‐resolution computed tomography (HRCT) were performed. Soluble forms (s) of PD‐L1, PD‐L2, TIM‐3, and GAL‐9 were evaluated in serum and cell culture supernatant, as well as T‐cells subsets and the transmembrane expression of PD‐L1 and PD‐L2 on the cell surface. Results: Eighty percent of the post‐COVID‐ILD patients normalized their lung function at 1‐year follow‐up, 8% presented COVID‐independent ILD, and 12% still showed functional and HRCT alterations. PD‐L2 levels were heterogeneous during acute COVID‐19 (aCOVID); patients who increased (at least 30%) their sPD‐L2 levels at 1 year post‐COVID‐19 and exhibited altered CD4/CD8 ratio showed persistence of chest tomographic and functional alterations. By contrast, patients who decreased sPD‐L2 displayed a complete lung recovery. sPD‐L1, sTIM‐3, and sGAL‐9 increased significantly during aCOVID and decreased in all patients after 1‐year follow‐up. Conclusion: Increased sPD‐L2 and an altered CD4/CD8 ratio after 12 months of aCOVID are associated with the persistence of lung lesions, suggesting that they may contribute to lung damage post‐COVID‐19. [ABSTRACT FROM AUTHOR]

Background: The emergence of new SARS‐CoV‐2 variants and the global COVID‐19 pandemic spurred urgent vaccine development. While common vaccine side effects are well‐documented, rare adverse events necessitate post‐marketing surveillance. Recent research linked messenger RNA vaccines to thrombotic microangiopathy (TMA), a group of syndromes characterized by microvascular hemolytic anemia and thrombocytopenia. This report describes a new‐onset atypical hemolytic‐uremic syndrome (aHUS) occurring after COVID‐19 vaccination and complements recent literature. Case Presentation: A previously healthy 25‐year‐old woman developed malaise, nausea, edema, and renal dysfunction 60 days postvaccination. Laboratory findings confirmed TMA diagnosis. Genetic testing for complement system mutations was negative. Kidney biopsy supported the diagnosis, and the patient required hemodialysis. Conclusion: This case illustrates the rare occurrence of aHUS following COVID‐19 vaccination, with unique characteristics compared to previous reports. Despite the critical role of vaccination in pandemic control, emerging adverse events, such as vaccine‐related TMA, must be recognized and investigated. Additional clinical trials are imperative to comprehend the clinical features and pathophysiological mechanisms underlying TMA associated with COVID‐19 vaccination. [ABSTRACT FROM AUTHOR]

The SARS‐CoV‐2 VIrus PERsistence (VIPER) study investigated the presence of long‐lasting SARS‐CoV‐2 RNA in plasma, stool, urine, and nasopharyngeal samples in COVID‐19 survivors. The presence of SARS‐CoV‐2 RNA reverse transcription polymerase chain reactions (RT‐PCR) were analyzed within plasma, stool, urine, and nasopharyngeal swab samples in COVID‐19 survivors with post‐COVID symptoms and a comparison group of COVID‐19 survivors without post‐COVID symptoms matched by age, sex, body mass index and vaccination status. Participants self‐reported the presence of any post‐COVID symptom (defined as a symptom that started no later than 3 months after the initial infection). Fifty‐seven (57.9% women, age: 51.1, standard deviation [SD]: 10.4 years) previously hospitalized COVID‐19 survivors with post‐COVID symptoms and 55 (56.4% women, age: 50.0, SD: 12.8 years) matched individuals who had a past SARS‐CoV‐2 infection without post‐COVID symptoms were evaluated 27 (SD 7.5) and 26 (SD 8.7) months after hospital discharge, respectively. The presence of SARS‐CoV‐2 RNA was identified in three nasopharyngeal samples of patients with post‐COVID symptoms (5.2%) but not in plasma, stool, or urine samples. Thus, SARS‐CoV‐2 RNA was not identified in any sample of survivors without post‐COVID symptoms. The most prevalent post‐COVID symptoms consisted of fatigue (93%), dyspnea, and pain (both, 87.7%). This study did not find SARS‐CoV‐2 RNA in plasma, stool, or urine samples, 2 years after the infection. A prevalence of 5.2% of SARS‐CoV‐2 RNA in nasopharyngeal samples, suggesting a potential active or recent reinfection, was found in patients with post‐COVID symptoms. These results do not support the association between SARS‐CoV‐2 RNA in plasma, stool, urine, or nasopharyngeal swab samples and post‐COVID symptomatology in the recruited population. [ABSTRACT FROM AUTHOR]

Introduction: The last two decades have seen a shift towards blended learning in education due to technological advancements. This study focuses on dental education, comparing two blended learning models ‐enriched virtual and fully online flipped classroom ‐ in terms of academic achievement, aligning with the Association for Dental Education in Europe's competencies. Materials and Methods: The research was modelled in a quantitative design with a pre–post‐test control group experimental design. The study was conducted at Ege University Faculty of Dentistry in Turkey for 4 weeks with the experimental (n = 44) and control (n = 39) groups divided into two groups by impartial assignment. To the experimental group, the theoretical part of the course was tried to be conveyed before each lesson with video lessons prepared with EdPuzzle containing reinforcement questions and a question set consisting of case questions. The practical learning objectives of the course were tried to be gained through the discussion of the previously presented case questions in the online synchronous course. As tools for collecting data, a unique academic achievement test, a course evaluation form and a semi‐structured qualitative data collection form were used. Results: It was seen that the flipped classroom model had a more positive effect on students' academic achievement than the enriched virtual classroom model. The general satisfaction levels of the participants regarding these two models are also higher in favour of the flipped classroom model. Conclusion: This study provides significant findings for educational institutions, policymakers and educators about the impact of fully online teaching methods on academic achievement. In this context, the flipped classroom method can be preferred both in cases where education is blocked and in dental education institutions that want to ensure digital transformation efficiently and partially remotely. [ABSTRACT FROM AUTHOR]

Postacute COVID‐19 sequelae affect millions of individuals, and active research into the pathophysiological mechanisms and potential treatments is underway. The report by Nara and colleagues shows persistent platelet hyperactivity in the chronic phase of the infection, suggesting a possible role of platelets in post‐COVID‐19 complications and, consequently, a possible therapeutic target. Commentary on: Nara et al. Prolonged platelet hyperactivity after COVID‐19 infection. Br J Haematol 2024;204:492‐496. [ABSTRACT FROM AUTHOR]

Background: Neurological symptoms associated with coronavirus disease 2019 (COVID‐19), such as fatigue and smell/taste changes, persist beyond infection. However, little is known of brain physiology in the post‐COVID‐19 timeframe. Purpose: To determine whether adults who experienced flu‐like symptoms due to COVID‐19 would exhibit cerebral blood flow (CBF) alterations in the weeks/months beyond infection, relative to controls who experienced flu‐like symptoms but tested negative for COVID‐19. Study Type: Prospective observational. Population: A total of 39 adults who previously self‐isolated at home due to COVID‐19 (41.9 ± 12.6 years of age, 59% female, 116.5 ± 62.2 days since positive diagnosis) and 11 controls who experienced flu‐like symptoms but had a negative COVID‐19 diagnosis (41.5 ± 13.4 years of age, 55% female, 112.1 ± 59.5 since negative diagnosis). Field Strength and Sequences: A 3.0 T; T1‐weighted magnetization‐prepared rapid gradient and echo‐planar turbo gradient‐spin echo arterial spin labeling sequences. Assessment: Arterial spin labeling was used to estimate CBF. A self‐reported questionnaire assessed symptoms, including ongoing fatigue. CBF was compared between COVID‐19 and control groups and between those with (n = 11) and without self‐reported ongoing fatigue (n = 28) within the COVID‐19 group. Statistical Tests: Between‐group and within‐group comparisons of CBF were performed in a voxel‐wise manner, controlling for age and sex, at a family‐wise error rate of 0.05. Results: Relative to controls, the COVID‐19 group exhibited significantly decreased CBF in subcortical regions including the thalamus, orbitofrontal cortex, and basal ganglia (maximum cluster size = 6012 voxels and maximum t‐statistic = 5.21). Within the COVID‐19 group, significant CBF differences in occipital and parietal regions were observed between those with and without self‐reported on‐going fatigue. Data Conclusion: These cross‐sectional data revealed regional CBF decreases in the COVID‐19 group, suggesting the relevance of brain physiology in the post‐COVID‐19 timeframe. This research may help elucidate the heterogeneous symptoms of the post‐COVID‐19 condition. Evidence Level: 2. Technical Efficacy: Stage 3. [ABSTRACT FROM AUTHOR]

Aims: This cohort study, based on Danish health registers, examined the post‐acute consequences of hospitalization for COVID‐19 in patients with diabetes. Methods: The study population comprised all Danish citizens (≥18 years old) who had diabetes when the pandemic started. A patient was exposed if he/she had a hospitalization with COVID‐19 after 1 March 2020. A patient was unexposed when he/she was not hospitalized with COVID‐19 between 1 March 2020 and the end of follow‐up (4 January 2022), or the first registered event of interest. The outcomes included post‐COVID‐19 hospitalizations and death. We used a Cox proportional hazards model with time varying exposure estimating the hazards ratio (HR) to analyze if the hazard for an outcome of interest was impacted by being hospitalized with COVID‐19. Results: In patients with type 1 diabetes, 101 were hospitalized with COVID‐19, and 25,459 were not. We did not have sufficient statistical power to identify differences in risk for those with type 1 diabetes. In type 2 diabetes, 1515 were hospitalized with COVID‐19, and 95,887 were not. The adjusted HRs of post‐acute hospitalization for respiratory diseases and infections were 1.71 (95% CI 1.45–2.03) and 1.87 (95% CI 1.61–2.18), respectively. The HR of death was 2.05 (95% CI 1.73–2.43). Patients with uncertain type had results similar to those with type 2 diabetes. Conclusions/Interpretation: In type 2 diabetes and diabetes of uncertain type, hospitalization with COVID‐19 was associated with an increased risk of post‐acute hospitalization for respiratory diseases, infections and death. [ABSTRACT FROM AUTHOR]

Following the innovations and new discoveries of the last 10 years in the field of lung ultrasound (LUS), a multidisciplinary panel of international LUS experts from six countries and from different fields (clinical and technical) reviewed and updated the original international consensus for point‐of‐care LUS, dated 2012. As a result, a total of 20 statements have been produced. Each statement is complemented by guidelines and future developments proposals. The statements are furthermore classified based on their nature as technical (5), clinical (11), educational (3), and safety (1) statements. [ABSTRACT FROM AUTHOR]

Background and Objective: Before and after the fandom, the pattern of education has difficulty in accepting the requirements of the MZ generation with very intense changes. Individual differences between students and different educational environments have more difficulties with the addition of practical subjects than general students. In this study of the purpose, after coronavirus disease‐19 (COVID‐19), the change in demand was described for the factors that influence the motivation necessary in current beauty education for diversity in education methods of MZ generation. Methods: These thesis studies are literature reviews, and for this purpose, a narrative review approach was used. A total of 200–300 references were selected and reviewed, and a total of papers were finally selected as of 2010–2022 using the PRISMA flow diagram. Results: With the emergence of diversity in education, online education is showing its power. In beauty education, the need for education of practical subjects has emerged and is the basis for providing more skilled skills in the field. This review paper conducted a comprehensive study on the motivational factors that will be the basis for the improved academic achievement of the MZ generation on the changes in education after COVID‐19. Conclusion: This literature review revealed the needs of the subjects of K‐education to be seen after the post‐COVID era and the factors of learning motivation required in the beauty distance education of the MZ generation. In addition, the global status of K‐beauty workers has confirmed that new changes with beauty and intelligence are being born as well as simple technical, and it is expected to be used as an important material for beauty distance education. [ABSTRACT FROM AUTHOR]

Sustainability issues are becoming increasingly important in the hospitality sector during crisis times such as COVID-19 and post-pandemic. In order to synthesize the literature on sustainable practices in hospitality, we developed a systematic literature to illustrate the dominant sustainable practices in hospitality. We present a comprehensive review of the 48 articles on sustainable practices in hospitality through the Web of Science (WoS) and Scopus databases; spanning over 2 years (2020-2021) pre-and amid the COVID-19 pandemic and extending the scope in distinctive ways. Our review has demonstrated that sustainable practices in hospitality have made progress in the years 2020 and 2021. However, there are conceptual and empirical overlaps among sustainable practices in hospitality. Additionally, hospitality sustainable practices research is restricted in research contexts. There is a lack of research on antecedents, outcomes, and integrating theories in studies. By following the guidance presented in this review, we expect to advance and maintain sustainable practices research to provide substantive insights over the coming years post-COVID-19. The current research is one of the first studies to systematically review sustainable practices in hospitality pre-and amid the COVID-19 pandemic. The research ends with a comprehensive research agenda and a framework to apprise future theoretical and empirical advances in the area. [ABSTRACT FROM AUTHOR]

Cancer patients are considered highly susceptible to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. However, it is not well known when chemotherapy can be safely restarted in cancer patients after coronavirus disease 2019 (COVID‐19). Here, we describe the case of an 18‐year‐old man diagnosed with primary mediastinal nonseminomatous germ cell tumor (PMNSGCT) in which chemotherapy could be safely restarted after COVID‐19. On day 11 of the third cycle of bleomycin, etoposide, plus cisplatin (BEP), he was diagnosed with mild COVID‐19. On day 16 after the onset of COVID‐19 (day 26 of third cycle of BEP), chemotherapy for his PMNSGCT was restarted. He received surgery after the fourth cycle of BEP without recurrence of COVID‐19. Chemotherapy could be restarted and followed by surgery in this post‐COVID‐19 patient who had experienced mild illness after the discharge criteria were met and all symptoms had disappeared. We report this case with a review of the literature on restarting chemotherapy after SARS‐CoV2 infection. [ABSTRACT FROM AUTHOR]

Objectives: Worldwide, lung ultrasound (LUS) was utilized to assess coronavirus disease 2019 (COVID‐19) patients. Often, imaging protocols were however defined arbitrarily and not following an evidence‐based approach. Moreover, extensive studies on LUS in post‐COVID‐19 patients are currently lacking. This study analyses the impact of different LUS imaging protocols on the evaluation of COVID‐19 and post‐COVID‐19 LUS data. Methods: LUS data from 220 patients were collected, 100 COVID‐19 positive and 120 post‐COVID‐19. A validated and standardized imaging protocol based on 14 scanning areas and a 4‐level scoring system was implemented. We utilized this dataset to compare the capability of 5 imaging protocols, respectively based on 4, 8, 10, 12, and 14 scanning areas, to intercept the most important LUS findings. This to evaluate the optimal trade‐off between a time‐efficient imaging protocol and an accurate LUS examination. We also performed a longitudinal study, aimed at investigating how to eventually simplify the protocol during follow‐up. Additionally, we present results on the agreement between AI models and LUS experts with respect to LUS data evaluation. Results: A 12‐areas protocol emerges as the optimal trade‐off, for both COVID‐19 and post‐COVID‐19 patients. For what concerns follow‐up studies, it appears not to be possible to reduce the number of scanning areas. Finally, COVID‐19 and post‐COVID‐19 LUS data seem to show differences capable to confuse AI models that were not trained on post‐COVID‐19 data, supporting the hypothesis of the existence of LUS patterns specific to post‐COVID‐19 patients. Conclusions: A 12‐areas acquisition protocol is recommended for both COVID‐19 and post‐COVID‐19 patients, also during follow‐up. [ABSTRACT FROM AUTHOR]

Aim: We investigated prolonged symptoms in children after COVID‐19, including the clinical characteristics and risk factors. Methods: This multicentre retrospective study focused on 451 children under 18 years old who were diagnosed with symptomatic COVID‐19 between 14 March and 31 December 2020. Persistent symptoms were analysed with a telephone questionnaire by the attending physicians from 1 August to 30 September 2021. A control group of 98 with no history of COVID‐19, who were treated for other reasons, was also included. Results: Most (82.0%) of the cases had mild infections that required outpatient care and 5.1% were admitted to the paediatric intensive care unit (PICU). We found that 18.4% had symptoms that lasted 4–12 weeks. There were also 14.6% who were symptomatic for longer than 12 weeks and the odds risks were higher for children aged 5 years or more (OR 3.0), hospitalised (OR 3.9), admitted to the PICU (OR 4.3) and with relatives who were symptomatic for 12 weeks or more (OR 2.8). The controls had similar percentages of prolonged symptoms, despite having no history of COVID‐19, especially those who were older than 5 years. Conclusion: This study confirmed that a worrying percentage of children had prolonged symptoms after COVID‐19. [ABSTRACT FROM AUTHOR]

The frequency, severity, and forms of symptoms months after coronavirus 2019 (COVID‐19) are poorly understood, especially in community settings. To better understand and characterize symptoms months after community‐based COVID‐19, a retrospective cohort analysis was conducted. Three hundred and twenty‐eight consecutive persons with a positive test for SARS‐CoV‐2 in the Johns Hopkins Health System, Maryland, March−May 2020, were selected for the study. Symptom occurrence and severity were measured through questionnaires. Of 328 persons evaluated, a median of 242 days (109−478 days) from the initial positive SARS‐CoV‐2 test, 33.2% reported not being fully recovered and 4.9% reported symptoms that constrained daily activities. Compared to those who reported being fully recovered, those with post‐acute sequelae were more likely to report a prior history of heart attack (p < 0.01). Among those reporting long‐term symptoms, men and women were equally represented (men = 34.8%, women = 34.6%), but only women reported symptoms that constrained daily activities, and 56% of them were caregivers. The types of new or persistent symptoms varied, and for many, included a deviation from prior COVID‐19 health, such as being less able to exercise, walk, concentrate, or breathe. A limitation is that self‐report of symptoms might be biased and/or caused by factors other than COVID‐19. Overall, even in a community setting, symptoms may persist months after COVID‐19 reducing daily activities including caring for dependents. Key points: •Even months after coronavirus 2019 a substantial proportion of persons continue to have symptoms that might restrict their daily activities.•Further research is needed to prevent this complication especially as the pandemic spreads over the world. [ABSTRACT FROM AUTHOR]

Introduction: Data on post‐COVID‐19 in renal transplant recipients (RTR) is scarce. We investigated the rate of hospitalizations, reasons for hospital admission, and mortality rate among RTR who survived acute COVID‐19. Methods: A multi‐center retrospective observational cohort study measured hospital admission and death to 180 days after acute SARS‐CoV‐2 infection in 308 adult patients. Results: The median age was 57 years, 64.9% were male. All patients had at least one comorbidity, and 26.3% had diabetes. Data on post‐COVID‐19 course was available for 267 patients, and 49 of them (15.9%) required hospital treatment after recovery from the acute infection. The most common indications included pneumonia (24.5%) and renal allograft dysfunction (22.4%), 7 (14.3%) had sepsis and 5 (10.2%) had thrombotic events. A median duration of the hospital stay was 12 days. Six patients (2.2%) died due to multiorgan failure, respiratory insufficiency or urosepsis. The strongest predictor for hospitalization after acute COVID‐19 was hospitalization for acute SARS‐CoV‐2 infection, while better allograft function decreased the probability of hospitalization. Conclusion: Delayed consequences of acute COVID‐19 are highly prevalent and the health care systems should be prepared to respond to the needs of RTR suffering from post‐COVID‐19 complications. [ABSTRACT FROM AUTHOR]

This systematic review focuses on the clinical features, physical examination findings, outcomes, and underlying pathology of acute telogen effluvium (TE), a type of diffuse hair loss, occurring in coronavirus disease 2019 (COVID‐19) recovered patients. MEDLINE/PubMed and Embase databases were queried till October 2021 to identify studies reporting acute TE occurring after COVID‐19 recovery. Data were obtained from 19 studies, which included 465 patients who were diagnosed with acute TE. The median age of these patients was 44 years and 67.5% were females. The most common trichoscopic findings were decreased hair density, the presence of empty follicles, or short regrowing hair. The mean duration from COVID‐19 symptom onset to the appearance of acute TE was 74 days, which is earlier than classic acute TE. Most patients recovered from hair loss, while a few patients had persistent hair fall. Our results highlight the need to consider the possibility of post‐COVID‐19 acute TE in patients presenting with hair fall, with a history of COVID‐19 infection, in the context of COVID‐19 pandemic. Despite being a self‐limiting condition, hair loss post‐COVID‐19 is a stressful manifestation. Identifying COVID‐19 infection as a potential cause of acute TE will help the clinicians counsel the patients, relieving them from undue stress. [ABSTRACT FROM AUTHOR]

Mucormycosis is a rare, invasive, quickly progressing fungal infection that generally affects patients who are immunocompromised. If left untreated, the disease is characterized by progressive necrosis and is often fatal. We present two cases of post‐COVID‐19 mucormycosis with a history of several years of uncontrolled diabetic mellitus. Mucormycosis is an opportunistic invasive fungal infection that commonly affects patients who are immunocompromised. If left untreated, it is often fatal following rhinocerebral involvement. [ABSTRACT FROM AUTHOR]

Background: While much of the scientific focus thus far has been on cognitive sequelae in patients with severe COVID‐19, subjective cognitive complaints are being reported across the spectrum of disease severity, with recent studies beginning to corroborate patients' perceived deficits. In response to this, the aims of this study were to (1) explore the frequency of impaired performance across cognitive domains in post‐COVID patients with subjective complaints and (2) uncover whether impairment existed within a single domain or across multiple. Methods: Sixty‐three patients with subjective cognitive complaints post‐COVID were assessed with a comprehensive protocol consisting of various neuropsychological tests and mood measures. Cognitive test performance was transformed into T scores and classified based on recommended guidelines. After performing a principal component analysis to define cognitive domain factors, distributions of test scores within and across domains were analyzed. Results: Results revealed pervasive impact on attention abilities, both as the singularly affected domain (19% of single‐domain impairment) as well as coupled with decreased performance in executive functions, learning, and long‐term memory. These salient attentional and associated executive deficits were largely unrelated to clinical factors such as hospitalization, disease duration, biomarkers, or affective measures. Discussion: These findings stress the importance of comprehensive evaluation and intervention to address cognitive sequelae in post‐COVID patients of varying disease courses, not just those who were hospitalized or experienced severe symptoms. Future studies should investigate to what extent these cognitive abilities are recuperated over time as well as employ neuroimaging techniques to uncover underlying mechanisms of neural damage. [ABSTRACT FROM AUTHOR]

Introduction: Follow‐up studies of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in kidney transplant recipients (KTR) are scarcely reported. Methods: We studied 142 hospitalized KTR for a median (interquartile range) follow‐up of 9 (8–11) months who recovered from SARS‐CoV‐2 during May 2020 to Dec 2020. The outcomes were to assess persistent symptoms post‐discharge; EuroQoL visual analogue score (EQ‐VAS); EuroQoL 5‐dimension score (E5‐QD‐5L) score and modified medical research dyspnea score (mMRC) at 1 month, 3‐month, and beyond 6 months. Graft outcome was also analyzed. Results: The age of the cohort was 43 (34–69) years and COVID‐19 severity ranged from asymptomatic (4%), mild (50%), moderate (35%) to severe (12%). The most common persistent symptom was fatigue which significantly decreased in the follow‐up (n = 45 [32.3] vs. 10 [7.4] vs. 4 [2.9]; p‐value = 0.001) at 1‐month, 3‐month, and beyond 6 months respectively. Decrement in the mean (standard deviation) EQ‐VAS score from baseline was also improved (28.6 [13] vs. 10.4 [12.5] vs. 7.5 [12.0]; p‐value = 0.012). There was significant improvement in all EQ‐5D‐5L scores in follow‐up. There was no deterioration in mMRC scores during the follow‐up (n = 4, 3% vs. 7, 5% vs. 3, 2%; p‐value = 0.86). Cases requiring oxygen had significantly poorer overall scores initially, but there was no difference at 6 months. All 10 graft losses had oxygen requirement and chronic graft dysfunction at baseline. Conclusion: Our initial assessment reports significant improvement in the quality of life in follow‐up. The majority recovered from allograft dysfunction. Further research is warranted to study the full spectrum of follow‐up. [ABSTRACT FROM AUTHOR]

Introduction: Although most patients recover within several weeks after acute COVID-19, some of them develop long-lasting clinical symptoms. Renal transplant recipients have an increased mortality risk from COVID-19. We aimed to describe complications occurring after COVID-19 in this group of patients. Methods: A prospective single-center cohort study was conducted at University Hospital Centre Zagreb. Patients with two negative reverse transcriptase-polymerase chain reaction (RT-PCR) tests for SARS-CoV-2 after COVID-19 were eligible for further follow-up at our outpatient clinic. They underwent detailed clinical and laboratory assessments. The primary outcome was the development of complications after COVID-19. Results: Only 11.53% of renal transplant recipients who survived acute COVID-19 were symptomless and free from new-onset laboratory abnormalities during the median follow-up of 64 days (range: 50-76 days). Three patients died from sepsis after discharge from the hospital. In 47 patients (45.2%), clinical complications were present, while 74 patients (71.2%) had one or more laboratory abnormalities. The most common clinical complications included shortness of breath (19.2%), tiredness (11.5%), peripheral neuropathy (7.7%), self-reported cognitive impairments (5.7%), and dry cough (7.7%). Most common laboratory abnormalities included shortened activated partial thromboplastin time (50%), elevated D-dimers (36.5%), elevated fibrinogen (30.16%), and hypogammaglobulinemia (24%). Positive RT-PCR for cytomegalovirus (8.7%), Epstein-Barr virus (26%), or BK virus (16.3%). Multivariate analysis identified the history of diabetes mellitus and eGFR CKD-EPI as predictors for the development of post-COVID clinical complications. Six months after acute COVID-19, elevated D-dimers persisted with normalization of other laboratory parameters. Twenty-nine patients were hospitalized, mostly with several concomitant problems. However, initially reported clinical problems gradually improved in the majority of patients. Conclusion: Post-COVID-19 clinical and laboratory complications are frequent in the renal transplant population, in some of them associated with significant morbidity. All patients recovered from acute COVID-19 should undergo long-term monitoring for evaluation and treatment of complications. [ABSTRACT FROM AUTHOR]

Background and aims: Dyspnea is one of the most common symptoms associated with the COVID‐19 caused by novel coronavirus SARS‐CoV‐2. This study aimed to assess the prevalence of dyspnea, observe co‐variables, and find predictors of dyspnea after 2 months of recovery from COVID‐19. Methods: A total of 377 patients were included in the study based on their responses and clinical findings during initial admission to the hospital with COVID‐19. After excluding five deceased patients, a total of 327 patients were interviewed through telephone using a 12‐point dyspnea scale and using relevant questions to gauge the patient clinically. Interviews were carried out by trained physicians, and responses were recorded and stored. All analyses were carried out using the statistical programming language R. Results: Of the total 327 participants in the study, 34% had stated that they were suffering from respiratory symptoms even after 2 months of COVID‐19. The study demonstrated that patient oxygen saturation level SpO2 (P = .03), D‐dimer (P = .001), serum ferritin (P = .006), and the presence and severity of dyspnea are significantly correlated. In addition to that, patient smoking history (P = .012) and comorbidities such as chronic obstructive pulmonary disease (COPD) (P = .021) were found to be statistically significant among groups. Conclusion: These findings of this study can be useful for predicting and managing long‐term complications of COVID‐19. [ABSTRACT FROM AUTHOR]

SARS-CoV-2 infection should be considered among the possible causes of myoclonus-ataxia syndrome also in immunocompetent patients with mild COVID-19 manifestations. Keywords: SARS-CoV-2 infection; post-COVID-19; myoclonus; ataxia; immunoglobulin EN SARS-CoV-2 infection post-COVID-19 myoclonus ataxia immunoglobulin S6 S8 3 09/20/22 20220903 NES 220903 During the coronavirus disease 2019 (COVID-19) pandemic, multisystemic syndromes related to viral infection have been described, with a range of neurological manifestations rapidly expanding.1,2 The commonly described and autoptically confirmed neurological disorders associated with COVID-19 include encephalitis, meningitis, anosmia/ageusia, Guillain-Barré syndrome, acute disseminated encephalomyelitis, and cerebrovascular events.3 Herein we report an emerging neurological manifestation associated with COVID-19, that is, myoclonus-ataxia syndrome. Video content can be viewed at https://onlinelibrary.wiley.com/doi/10.1002/mdc3.13534 Discussion We report a case of post-COVID-19 myoclonus-ataxia syndrome in a fully immunocompetent patient successfully treated with IVIg. [Extracted from the article]

Administration of molecular hydrogen dissolved in water to patient with COVID‐19‐like symptoms may improve oxygen levels and exercise capacity. [ABSTRACT FROM AUTHOR]

One year after the outbreak of coronavirus disease 2019 (COVID‐19), referrals for persistent headache, often defined as "post‐COVID headache," have become increasingly common in outpatient headache clinics. However, it is important to take into consideration that this term may include a spectrum of clinically different headache types. We describe three cases of migraine‐like headaches in individuals with a history of mild COVID‐19 infection to demonstrate some of the different phenotypes of persistent headaches seen. These cases highlight the importance of a careful evaluation when assessing the complexities of "post‐COVID headache" as well as the need to further investigate the different, underlying, pathophysiological mechanisms. [ABSTRACT FROM AUTHOR]

Due to long corticosteroid therapy in patients with COVID‐19, in case of cough, dyspnea, and weight loss, emerging pulmonary aspergillosis and lophomoniasis should be ruled out. [ABSTRACT FROM AUTHOR]

Worsening of clinical symptoms after COVID‐19 infection and misregulation of CD4 and CD8 T‐cell numbers may be revealed in PD patients. Immunological changes may be a source of clinical worsening of the patient. [ABSTRACT FROM AUTHOR]

References 1 Filip P, Jaroslaw S. Post-COVID-19 myoclonus-ataxia syndrome - Is there really a need for intravenous immunoglobulin treatment in all cases? Keywords: SARS-CoV-2 infection; post-COVID-19; myoclonus; ataxia; immunoglobulin EN SARS-CoV-2 infection post-COVID-19 myoclonus ataxia immunoglobulin 726 727 2 04/18/23 20230401 NES 230401 We thank Drs. Reply: Post-COVID-19 Myoclonus-Ataxia Syndrome - Is there Really a Need for Intravenous Immunoglobulin Treatment in all Cases?. [Extracted from the article]

The article describes the cases of 21 post-COVID-19 patients who had oral mucormycosis. Topics include descriptive data of palatal lesions among the post-COVID-19 patients with oral mucormycosis, oral manifestations of mucormycosis in COVID-19 patients, and important role of dentists in mucormycosis patients.